Note: The figures below are illustrative estimates based on publicly available data and typical industry practices. Actual manufacturing costs for mirtazapine (Remeron®) can vary widely depending on scale, location, supplier agreements, quality‑control requirements, and other factors. The retail or wholesale price of the finished drug is typically several times higher than the raw‑material and manufacturing cost because it also includes R&D amortization, regulatory compliance, marketing, distribution, and profit margins.
1. What drives the cost of producing mirtazapine?
| Cost component |
Typical influence on total cost |
Key variables |
| Active Pharmaceutical Ingredient (API) |
Major portion (~30–50 % of total cost) |
Cost of the starting material, synthesis route complexity, catalyst recycling, yields |
| Raw Materials & Reagents |
10–20 % |
Quality grade, purity, supplier contracts |
| Labor & Facilities |
15–25 % |
Labor rates, plant capacity, equipment depreciation, energy costs |
| Quality Control & Testing |
5–10 % |
Number of tests, analytical equipment, staffing |
| Regulatory & Compliance |
5–10 % |
GMP audits, documentation, certifications |
| Packaging & Labeling |
2–5 % |
Material costs, design, printing |
| Overheads & Miscellaneous |
5–10 % |
Insurance, shipping, waste disposal, contingency |
Bottom line: The API is usually the biggest cost driver, but the total manufacturing cost is a combination of many moving parts.
2. Rough cost ballpark for mirtazapine
| Stage |
Rough cost range (USD) |
Notes |
| API production |
$1,500 – $3,500 per kilogram |
Depends on synthesis route; some reports suggest ~ $2,200–$3,000/kg for a commercial‑grade API |
| Formulation & packaging |
$0.50 – $1.00 per tablet |
Includes excipients, compression, coating, blister pack, labeling |
| Quality & regulatory |
$0.10 – $0.30 per tablet |
Analytical testing, GMP compliance |
| Total per‑tablet cost |
$0.75 – $1.30 |
Adds up the above components; does not include R&D amortization or marketing |
Example:
- A 20 mg tablet (standard adult dose) might cost roughly $0.90 to manufacture under typical commercial conditions.
- A 10 mg tablet would cost proportionally less, perhaps $0.45–$0.60.
These numbers are highly indicative and can shift depending on regional cost structures, economies of scale, and negotiated supplier pricing.
3. Why the retail/wholesale price is higher
- R&D amortization – The initial discovery, pre‑clinical studies, clinical trials, and regulatory approvals often cost tens of millions of dollars. Companies spread this across many thousands of doses.
- Marketing & sales – Advertising, physician education, and market access costs.
- Distribution – Logistics, warehousing, and retail margins.
- Profit margin – Companies need to achieve a return on investment.
For example, in the United States, a 20 mg mirtazapine tablet may retail for $4–$7 (brand‑name) or $0.50–$1.20 (generic), well above the manufacturing cost.
4. Where can you find more detailed cost data?
| Source |
What you’ll find |
How to access |
| Pharma industry reports (e.g., IQVIA, EvaluatePharma) |
Market size, pricing trends, production cost estimates |
Subscription or purchase |
| Public filings (SEC 10‑K, annual reports) |
Company‑specific cost breakdowns, R&D spend |
Open‑access on company websites |
| Academic literature |
Studies on synthetic routes and cost analyses |
PubMed, Google Scholar |
| Industry conferences |
Presentations on process economics |
Conference programs, webinars |
5. Key take‑aways
- Manufacturing cost ≈ 10–30 % of the final retail price.
- API costs dominate (~30–50 % of manufacturing cost).
- Scaling up (e.g., multi‑tons vs. small‑batch production) can lower per‑unit cost by up to 20–30 %.
- Regulatory, quality, and packaging costs add 10–20 % to the total.
If you need precise numbers for a specific manufacturing setup, you’ll likely need to consult a contract manufacturer or a detailed techno‑economic analysis tailored to your production parameters.